38
Prevention and early treatment of COVID-19

Prevention and early treatment of COVID-19€¦ · 7.4% 58.4% Percentage of household contacts with COVID-19 symptoms Shouman W. NCT04422561 p < .05 Prophylaxis of household contacts

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

  • Prevention and early

    treatment ofCOVID-19

  • FOUNDING MEMBERS

    • March 2020• FLCCC formed by leading

    Critical Care specialists• Non-profit • Mission: Develop effective

    COVID-19 treatment protocols

    • Prevent COVID-19 transmission

    • Improve patient outcomes

  • Hospital protocol

    created by the FLCCC in

    March 2020

  • December 4, 2020A CALL-TO-ACTION

    IN A TIME OF A NATIONAL AND GLOBAL HEALTH

    CRISIS

  • NATIONAL CALL-TO-ACTIONVaccines are coming,

    but they are onlypart of the solution.

  • Electronic Press Kit:flccc.net

  • FRONT LINE COVID-19 CRITICAL CARE ALLIANCEPROPHYLAXIS & TREATMENT PROTOCOLS FOR COVID-19

    PROPHYLAXIS PROTOCOL

    lvermectin Prophylaxis for high risk individuals 0.2 mg/kg* — one dose on day 1 and day 3, then take

    one dose every 4 weeks

    Post COVID-19 exposure prophylaxis** 0.2 mg/kg* — one dose on day 1 and day 3

    Vitamin D3 1,000–3,000 IU/day

    Vitamin C 1,000 mg twice a day

    Quercetin 250 mg/day

    Zinc 50 mg/day

    Melatonin 6 mg before bedtime (causes drowsiness)

    EARLY OUTPATIENT PROTOCOL***

    lvermectin 0.2 mg/kg* — one dose on day 1 and day 3

    Vitamin D3 4,000 IU/day

    Vitamin C 2,000 mg 2–3 times daily

    Quercetin 250 mg twice a day

    Zinc 100 mg/day

    Melatonin 10 mg before bedtime

    Aspirin 325 mg/day (unless contraindicated)

    * ≈ 0.09 mg/lb per dose (take on an empty stomach with water). Example for a person of 60 kg (body weight): 60 kg × 0.2 mg = 12 mg — please see conversion table (kg lbs) on page 2 to calculate the appropriate ivermectin dose.

    ** To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask

    *** For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treat ment Protocol for COVID-19 on www.flccc.net

    Page 1/2

    Please regard our disclaimer and further information on page 2 of this document.

    www.flccc.net © 2020 FLCCC Alliance · I-MASK+ Protocol v5 · Nov. 28, 2020 Layout

    & t

    ypes

    etti

    ng

    by

    rau

    mfi

    sch

    .de/

    sig

    n

    Must wear cloth, surgical,

    or N95 mask (without valve)

    in all indoor spaces with non-

    household persons.

    Must wear a N95 mask

    (without valve) during pro-

    longed exposure to non-

    household persons in any

    confined, poorly ventilated

    area.

    WEAR MASKS

    KEEP DISTANCE

    Until the end of the Covid-19

    crisis, we recommend keep -

    ing a minimum dis tance of

    approx. 2 m / 6 feet in public

    from people who are not

    from your own household.

    WASH HANDS

    We recommend, after a stay

    during and after outings

    from home (shopping, sub-

    way etc.), a thorough hand

    cleaning (20–30 sec. with

    soap), or also to use a hand

    disinfectant in between.

    Behavioral Prophylaxis

    PROPHYLAXIS & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19

    FRONT LINE COVID-19 CRITICAL CARE ALLIANCEPROPHYLAXIS & TREATMENT PROTOCOLS FOR COVID-19

    PROPHYLAXIS PROTOCOL

    lvermectin Prophylaxis for high risk individuals 0.2 mg/kg* — one dose on day 1 and day 3,

    then take one dose every 4 weeks

    Post COVID-19 exposure prophylaxis** 0.2 mg/kg* — one dose on day 1 and day 3

    Vitamin D3 1,000–3,000 IU/day

    Vitamin C 1,000 mg twice a day

    Quercetin 250 mg/day

    Zinc 50 mg/day

    Melatonin 6 mg before bedtime (causes drowsiness)

    EARLY OUTPATIENT PROTOCOL***

    lvermectin 0.2 mg/kg* — one dose on day 1 and day 3

    Vitamin D3 4,000 IU/day

    Vitamin C 2,000 mg 2–3 times daily

    Quercetin 250 mg twice a day

    Zinc 100 mg/day

    Melatonin 10 mg before bedtime

    Aspirin 325 mg/day (unless contraindicated)

    * ≈ 0.09 mg/lb per dose (take on an empty stomach with water). Example for a person of 60 kg (body weight): 60 kg × 0.2 mg = 12 mg — please see conversion table (kg lbs) on page 2 to calculate the appropriate ivermectin dose.

    ** To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask

    *** For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treat ment Protocol for COVID-19 on www.flccc.net

    Page 1/2

    Please regard our disclaimer and further information on page 2 of this document.

    www.flccc.net © 2020 FLCCC Alliance · I-MASK+ Protocol v5 · Nov. 28, 2020 Layout

    & t

    ypes

    etti

    ng

    by

    rau

    mfi

    sch

    .de/

    sig

    n

    Must wear cloth, surgical,

    or N95 mask (without valve)

    in all indoor spaces with non-

    household persons.

    Must wear a N95 mask

    (without valve) during pro-

    longed exposure to non-

    household persons in any

    confined, poorly ventilated

    area.

    WEAR MASKS

    KEEP DISTANCE

    Until the end of the Covid-19

    crisis, we recommend keep -

    ing a minimum dis tance of

    approx. 2 m / 6 feet in public

    from people who are not

    from your own household.

    WASH HANDS

    We recommend, after a stay

    during and after outings

    from home (shopping, sub-

    way etc.), a thorough hand

    cleaning (20–30 sec. with

    soap), or also to use a hand

    disinfectant in between.

    Behavioral Prophylaxis

    PROPHYLAXIS & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19

  • • 40-year-old anti-parasitic drug• Discovery awarded Nobel Prize in 2015 • On the W.H.O.’s list of “essential medicines.”

  • Used safely by 3.7 billionpeople worldwide.

  • High activity against COVID19• Pre-Exposure• Post-Exposure• Early Symptoms• Late Stage Disease

  • New and compelling data has emerged since August—the last time the N.I.H.

    updated their recommendations

  • Electronic Press Kit:flccc.net

  • Studies show consistent,

    reproducible efficacy of Ivermectin.

  • Prophylaxis Trials of > 1,100 patients•3 Randomized Controlled Trials

    •1 Observational Trial

  • 0,00%

    15,00%

    30,00%

    45,00%

    60,00%

    75,00%

    Ivermectin Prophylaxis, N=228 No Prophlaxis, N=112

    7.4%

    58.4%Percentage

    of household contacts with

    COVID-19 symptoms

    Shouman W. NCT04422561 p < .05

    Prophylaxis of household contacts of COVID-19 patients Randomized, Controlled Trial

    Zagazig University, Egypt

  • 0,

    17,5

    35,

    52,5

    70,

    Ivermectin Prophylaxis, N=91 No Prophylaxis, N=281

    16.4%

    60.8%

    Behera P et al., https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.full (2020)

    Prophylaxis of health care workers studyObservational Controlled Trial

    All India Institute of Medical Sciences

    Percentage of health care

    workers who contracted

    COVID-19

  • 0,

    0,03

    0,05

    0,08

    0,1

    0,13

    Ivermecin Prophylaxis, N=100 No Prophylaxis, N=100

    A. Elgazzar et al., https://www.researchsquare.com/article/rs-100956/v2 (2020)

    2.0%

    10.0%

    Percentage of health care and

    household contacts who

    contracted COVID-19

    Prophylaxis of household and health care worker contacts of COVID-19 patients

    Randomized Controlled Trial

  • Carvallo H. https://clinicaltrials.gov/ct2/show/NCT04425850 (2020)

    0,

    0,03

    0,06

    0,09

    0,12

    Ivermectin Prophlaxis, N=131No Ivermectin Prophylaxis, N=98

    0.0%

    11.2%

    Percentage of healthy citizens who contracted COVID-19 after

    28 days

    Prophylaxis of 229 Heathy CitizensRandomized Controlled Trial – Argentina

  • Long Term Care Facility A Long Term Care Facility B+C+D

  • Outpatient Trials – 500 Patients • 3 Randomized Controlled Trials

    • Large Case Series

  • Hospitalized Patient Trials4 Randomized Controlled Trials > 800 patients

    4 Observational Controlled Trials > 2000 patients

  • All available clinical trial results

    show major benefits of Ivermectin

    in prevention and treatment

  • Deaths in patients over 60 among 8 Peruvian states after deploying mass ivermectin treatment

  • Decreases in COVID-19 Case Fatality Rates in Peruvian patients over 60

  • PARAGUAY

  • Electronic Press Kit:flccc.net

  • NATIONAL CALL-TO-ACTIONNational & Global Health Authorities:

    Review Recent Clinical Trials Evidence Demonstrating Clinical Benefits of IVERMECTIN

  • Failed and successful Rx for COVID-19 by phase of illness*

    * Based on Randomized Controlled Trials

  • flccc.net

  • NATIONAL CALL-TO-ACTIONFollowing swift validation of evidence,

    health authorities are urged to issue guidelines for health care providers to prescribe

    IVERMECTIN

  • I-MASK+ will change the face of this disease worldwide.

  • Electronic Press Kit:flccc.net